HC Wainwright Has Lowered Expectations for Structure Therapeutics (NASDAQ:GPCR) Stock Price

Key Points

• HC Wainwright has lowered the price target for Structure Therapeutics from $75.00 to $60.00, but maintains a "buy" rating on the stock, suggesting a possible upside of 271.38%.
• Despite the downgrade by HC Wainwright, eight research analysts continue to rate the stock as a "buy," with an average target price of $75.71.
• Structure Therapeutics reported a quarterly loss of ($0.36) earnings per share, which was worse than analysts' expectations of ($0.28).

Structure Therapeutics (NASDAQ:GPCR - Free Report) had its price objective lowered by HC Wainwright from $75.00 to $60.00 in a research report released on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other equities research analysts also recently commented on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, June 23rd. JMP Securities lowered their target price on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a research note on Thursday. Citigroup initiated coverage on shares of Structure Therapeutics in a research note on Friday, May 2nd. They issued a "buy" rating and a $60.00 target price for the company. Finally, Guggenheim lowered their target price on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a research note on Thursday. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $75.71.

Structure Therapeutics Stock Up 7.4%

NASDAQ GPCR traded up $1.20 during trading hours on Thursday, hitting $17.51. The company's stock had a trading volume of 936,317 shares, compared to its average volume of 874,938. The stock has a fifty day moving average of $19.78 and a 200 day moving average of $21.76. Structure Therapeutics has a twelve month low of $13.22 and a twelve month high of $45.37. The firm has a market capitalization of $1.00 billion, a P/E ratio of -16.68 and a beta of -1.89.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.08). On average, analysts predict that Structure Therapeutics will post -0.82 earnings per share for the current year.

Institutional Trading of Structure Therapeutics

A number of large investors have recently added to or reduced their stakes in GPCR. GF Fund Management CO. LTD. acquired a new stake in Structure Therapeutics in the fourth quarter valued at $34,000. National Bank of Canada FI lifted its stake in Structure Therapeutics by 1,448.2% in the first quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock valued at $51,000 after acquiring an additional 2,766 shares during the last quarter. Assetmark Inc. lifted its stake in Structure Therapeutics by 39.9% in the second quarter. Assetmark Inc. now owns 2,877 shares of the company's stock valued at $60,000 after acquiring an additional 820 shares during the last quarter. Virtus ETF Advisers LLC lifted its stake in Structure Therapeutics by 25.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after acquiring an additional 455 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd lifted its stake in Structure Therapeutics by 310.7% in the first quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock valued at $74,000 after acquiring an additional 3,213 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.